What is NeuraLight?
Founded in 2021, NeuraLight operates at the intersection of artificial intelligence and clinical neurology. The company specializes in the digitization of neurological analysis, providing clinicians with data-driven insights that replace subjective observation with precise, quantifiable metrics. By focusing on the objective measurement of neurological health, NeuraLight addresses a critical gap in the treatment of chronic conditions, offering a scalable solution that enhances diagnostic accuracy and patient outcomes. Its market position is defined by its commitment to transforming traditional neurological care into a data-centric discipline, effectively bridging the gap between advanced machine learning and patient-facing medical services.
How much funding has NeuraLight raised?
NeuraLight has raised a total of $30.5M across 2 funding rounds:
Angel/Seed
$5.5M
Series A
$25M
Angel/Seed (2021): $5.5M with participation from VSC Ventures, Kli, Tuesday, MSAD, and Operator Partners
Series A (2022): $25M led by David Golan, Lily Sarafan, Koch Disruptive Technologies, Breyer Capital, Samsung NEXT, VSC Ventures, and Chris Mansi
Key Investors in NeuraLight
Breyer Capital
Breyer Capital is an independent global venture capital and private equity investor focusing on long-term, idea-driven investments in artificial intelligence and machine learning.
Samsung NEXT
Samsung NEXT provides software and services to complement Samsung's global hardware footprint, combining product development, investment, and M&A under one roof.
Koch Disruptive Technologies
Koch Disruptive Technologies is a venture capital firm focused on identifying and investing in transformative technologies that have the potential to disrupt existing industries.
What's next for NeuraLight?
With the successful closure of its latest funding round, NeuraLight is poised to accelerate its product roadmap and deepen its integration within the broader healthcare ecosystem. The company's strategic focus will likely center on scaling its diagnostic platform to meet the demands of large-scale clinical environments and enterprise health systems. As the firm continues to refine its algorithms, the emphasis will remain on securing regulatory milestones and expanding its reach to support a wider array of neurological disorders. This phase of growth is critical for establishing NeuraLight as a foundational player in the digital health infrastructure, ensuring that its technology becomes a standard tool for neurologists worldwide.
See full NeuraLight company page
